Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
### Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 2 years of age and older.
### Adult Dosing
* **LGS:** Initial dose: 5 mg twice daily. Titrate upwards by 5-10 mg every week as tolerated.
* **Maximum dose:** 20 mg twice daily.
### Pediatric Dosing (2 years and older)
* **LGS:** Initial dose: 5 mg twice daily. Titrate upwards by 5-10 mg every week as tolerated.
* **Maximum dose:** 20 mg twice daily.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider a lower starting dose and slower titration.
* **Renal Impairment:** No specific dose adjustment guidelines are established. Monitor for increased adverse effects.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, constipation, decreased appetite, fatigue, aggression, irritability, insomnia, ataxia, vomiting.
* **Serious:** Respiratory depression, somnolence (can be profound and dose-dependent), suicidal behavior and ideation, withdrawal symptoms upon abrupt discontinuation (seizures, tremor, abdominal/muscle cramps, vomiting, sweating, confusion, irritability).
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Additive CNS depressant effects, increasing risk of profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam plasma concentrations, potentially leading to increased adverse effects.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam plasma concentrations, potentially leading to reduced efficacy.
* **Other Anticonvulsants:** Clobazam can affect serum concentrations of other antiepileptic drugs (e.g., stiripentol). Monitor for efficacy and toxicity.
### Monitoring
* Monitor for efficacy in seizure control.
* Monitor for signs of somnolence, sedation, and CNS depression.
* Monitor for signs of withdrawal symptoms during dose reduction or discontinuation.
* Monitor for suicidal behavior and ideation.
### Clinical Pearls
* Clobazam can be administered as a single dose at bedtime for those experiencing excessive daytime somnolence.
* Discontinuation should occur gradually with a slow taper to minimize withdrawal symptoms.
* Due to the risk of somnolence and dizziness, patients should be advised to avoid operating heavy machinery or driving until they know how clobazam affects them.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant literature for complete details and to confirm the appropriateness of this information for your specific patient.*
